DE69714083D1 - Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori - Google Patents
Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pyloriInfo
- Publication number
- DE69714083D1 DE69714083D1 DE69714083T DE69714083T DE69714083D1 DE 69714083 D1 DE69714083 D1 DE 69714083D1 DE 69714083 T DE69714083 T DE 69714083T DE 69714083 T DE69714083 T DE 69714083T DE 69714083 D1 DE69714083 D1 DE 69714083D1
- Authority
- DE
- Germany
- Prior art keywords
- pct
- lactoperoxidase
- thiocyanate
- helicobacter pylori
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000590002 Helicobacter pylori Species 0.000 title abstract 2
- 108010023244 Lactoperoxidase Proteins 0.000 title abstract 2
- 102000045576 Lactoperoxidases Human genes 0.000 title abstract 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 title abstract 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 229940057428 lactoperoxidase Drugs 0.000 title abstract 2
- 150000002978 peroxides Chemical class 0.000 title abstract 2
- 229940037467 helicobacter pylori Drugs 0.000 title 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 2
- 102000010445 Lactoferrin Human genes 0.000 abstract 1
- 108010063045 Lactoferrin Proteins 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract 1
- 229940078795 lactoferrin Drugs 0.000 abstract 1
- 235000021242 lactoferrin Nutrition 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9600233A SE506529C2 (sv) | 1996-01-23 | 1996-01-23 | Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori |
PCT/SE1997/000098 WO1997026908A1 (en) | 1996-01-23 | 1997-01-22 | Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69714083D1 true DE69714083D1 (de) | 2002-08-22 |
DE69714083T2 DE69714083T2 (de) | 2003-03-27 |
Family
ID=20401114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69714083T Expired - Fee Related DE69714083T2 (de) | 1996-01-23 | 1997-01-22 | Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori |
Country Status (9)
Country | Link |
---|---|
US (1) | US6149908A (de) |
EP (1) | EP1007086B1 (de) |
JP (1) | JP2000509367A (de) |
AT (1) | ATE220556T1 (de) |
AU (1) | AU731221B2 (de) |
CA (1) | CA2243708C (de) |
DE (1) | DE69714083T2 (de) |
SE (1) | SE506529C2 (de) |
WO (1) | WO1997026908A1 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19710068A1 (de) * | 1997-03-12 | 1998-09-17 | Kramer Axel | Mittel zur Förderung der Mundhygiene und der Mundgesundheit |
US5972355A (en) * | 1997-09-30 | 1999-10-26 | E-L Management Corp. | Stable compositions containing biologically active components |
ATE233050T1 (de) | 1997-11-05 | 2003-03-15 | Koppert Bv | Bekämpfungsmittel gegen pflanzenpathogene mikro- organismen |
US6190667B1 (en) * | 1998-06-30 | 2001-02-20 | Institut Pasteur | Methods of inhibiting Helicobacter pylori |
US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
WO2000054792A1 (fr) * | 1999-03-17 | 2000-09-21 | Morinaga & Co., Ltd. | Medicaments, aliments, boissons et aliments pour animaux contenant un composant de cacao |
US6342528B1 (en) * | 2000-01-18 | 2002-01-29 | Lynntech, Inc. | Control of microbial populations in the gastrointestinal tract of animals |
WO2002015722A2 (en) * | 2000-08-21 | 2002-02-28 | Fahey Jed W | Treatment of helicobacter with isothiocyanates |
WO2002069958A1 (de) * | 2001-03-01 | 2002-09-12 | Wolfgang Weuffen | Thiocyanationen zur vorbeugung und therapie von bse und ähnlichen erkrankungen beim tier und menschen |
US7770577B2 (en) | 2001-05-15 | 2010-08-10 | Gregory E Conner | Methods and devices for treating lung dysfunction |
US6702998B2 (en) * | 2001-05-15 | 2004-03-09 | Gregory E. Conner | Methods and devices for treating lung dysfunction |
SE0200876L (sv) * | 2002-03-22 | 2003-09-23 | Krister Tano | Nässpray mot öroninflammationer |
NZ537089A (en) | 2003-02-24 | 2007-07-27 | Morinaga Milk Industry Co Ltd | Interleukin 6 production inhibitor |
WO2005018701A1 (en) * | 2003-08-25 | 2005-03-03 | Kane Biotech Inc. | Synergistic antimicrobial compositions and methods of inhibiting biofilm formation |
US7932069B2 (en) | 2004-02-17 | 2011-04-26 | Morinaga Milk Industry Co., Ltd. | Process for producing lactoperoxidase |
US20060289354A1 (en) * | 2005-06-15 | 2006-12-28 | Buckman Laboratories International, Inc. | Method and composition to control the growth of microorganisms in aqueous systems and on substrates |
US20070092502A1 (en) * | 2005-09-01 | 2007-04-26 | Allergan, Inc. | Method of Treating Glaucoma |
AU2006335883B2 (en) * | 2006-01-20 | 2011-04-28 | Morinaga Milk Industry Co., Ltd. | Pharmaceutical composition, food or drink, or feed for intestinal disease |
US20070197388A1 (en) * | 2006-02-22 | 2007-08-23 | Buckman Laboratories International, Inc. | Haloperoxidase treatment to control algae |
TR201900010T4 (tr) | 2006-07-03 | 2019-02-21 | Jean Paul Perraudin | Hipohalit ve/veya hipotiyosiyanit içeren antimikrobiyal bileşimler ve bunların kullanımları. |
GB0705557D0 (en) * | 2007-03-23 | 2007-05-02 | Stead Richard G | A treatment |
US8895282B2 (en) * | 2008-03-20 | 2014-11-25 | Tanomed Ab | Use of a substance for manufacturing of a medicament for treatment of common cold |
EP2346329B1 (de) | 2008-10-09 | 2013-08-21 | Anadys Pharmaceuticals, Inc. | Verfahren zur hemmung des hepatitis-c-virus mittels kombination aus einem 5,6-dihydro-1h-pyridin-2-on und einer oder mehreren antiviralen verbindungen |
JP2009215301A (ja) * | 2009-04-27 | 2009-09-24 | Morinaga Milk Ind Co Ltd | プロテアーゼ阻害剤 |
NZ600269A (en) * | 2009-05-20 | 2014-02-28 | Dec Int Nz Ltd | Delivery device for treatment of mastitis |
EP2540307B1 (de) * | 2010-02-24 | 2016-05-25 | Morinaga Milk Industry Co., Ltd. | Antibakterielles hilfsmittel mit einem kombu-extrakt als wirkstoff, antibakterielle zusammensetzung und nahrungsmittel oder getränk damit |
US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US11407713B2 (en) | 2011-01-03 | 2022-08-09 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US11279674B2 (en) | 2011-01-03 | 2022-03-22 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
US8865772B2 (en) | 2012-07-26 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating skin cancer |
US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
WO2014083048A1 (en) | 2012-11-30 | 2014-06-05 | Dsm Ip Assets B.V. | Synergistic fungicidal compositions containing lactoperoxidase system |
BR112016025331A2 (pt) | 2014-04-30 | 2017-08-15 | Matoke Holdings Ltd | composições antimicrobianas |
WO2016059654A1 (en) * | 2014-10-16 | 2016-04-21 | Giuseppe Baricco | Use of glucose oxidase for the control, the prevention and the cure of intestinal disorders |
GB2540130B (en) * | 2015-06-29 | 2021-04-14 | Institute Of Tech Sligo | A composition and a method for controlling bacterial infection |
GB201716986D0 (en) | 2017-10-16 | 2017-11-29 | Matoke Holdings Ltd | Antimicrobial compositions |
EP4309500A1 (de) | 2022-07-18 | 2024-01-24 | Acies Bio d.o.o. | Biokontrollmittel auf peroxidase-basis |
WO2024017883A1 (en) | 2022-07-18 | 2024-01-25 | Acies Bio D.O.O. | Peroxidase based biocontrol agents |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE420793B (sv) * | 1976-03-08 | 1981-11-02 | Astra Ewos Ab | Fodermedel innehallande ett antibakteriellt system |
US4578265A (en) * | 1981-08-13 | 1986-03-25 | Laclede Professional Products, Inc. | Di-enzymatic dentifrice |
US4564519A (en) * | 1983-06-06 | 1986-01-14 | Laclede Professional Products, Inc. | Di-enzymatic chewable dentifrice |
DK501686A (da) * | 1986-10-20 | 1988-04-21 | Otto Melchior Poulsen | Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det |
SE469004B (sv) * | 1989-03-07 | 1993-04-26 | Nobeltech Electronics Ab | Nattkikare |
FR2646777B1 (fr) * | 1989-05-12 | 1993-09-03 | Bio Serae Lab | Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications |
GB9002422D0 (en) * | 1990-02-03 | 1990-04-04 | Boots Co Plc | Anti-microbial compositions |
US5453284A (en) * | 1993-01-29 | 1995-09-26 | Pellico; Michael A. | Stabilized enzymatic dentifrice |
US5336494A (en) * | 1993-01-29 | 1994-08-09 | Pellico Michael A | Pet chewable products with enzymatic coating |
-
1996
- 1996-01-23 SE SE9600233A patent/SE506529C2/sv not_active IP Right Cessation
-
1997
- 1997-01-22 AT AT97901880T patent/ATE220556T1/de not_active IP Right Cessation
- 1997-01-22 CA CA002243708A patent/CA2243708C/en not_active Expired - Fee Related
- 1997-01-22 WO PCT/SE1997/000098 patent/WO1997026908A1/en active IP Right Grant
- 1997-01-22 AU AU15627/97A patent/AU731221B2/en not_active Ceased
- 1997-01-22 US US09/117,029 patent/US6149908A/en not_active Expired - Fee Related
- 1997-01-22 JP JP9526782A patent/JP2000509367A/ja active Pending
- 1997-01-22 DE DE69714083T patent/DE69714083T2/de not_active Expired - Fee Related
- 1997-01-22 EP EP97901880A patent/EP1007086B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
SE9600233L (sv) | 1997-07-24 |
DE69714083T2 (de) | 2003-03-27 |
SE506529C2 (sv) | 1997-12-22 |
SE9600233D0 (sv) | 1996-01-23 |
WO1997026908A1 (en) | 1997-07-31 |
ATE220556T1 (de) | 2002-08-15 |
EP1007086A1 (de) | 2000-06-14 |
CA2243708C (en) | 2007-04-24 |
AU1562797A (en) | 1997-08-20 |
CA2243708A1 (en) | 1997-07-31 |
EP1007086B1 (de) | 2002-07-17 |
US6149908A (en) | 2000-11-21 |
JP2000509367A (ja) | 2000-07-25 |
AU731221B2 (en) | 2001-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69714083D1 (de) | Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori | |
Sherman et al. | Maggot therapy: a review of the therapeutic applications of fly larvae in human medicine, especially for treating osteomyelitis | |
ATE256475T1 (de) | Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten | |
DE69636085D1 (de) | Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea | |
DE59610355D1 (de) | Medizinisches implantat | |
MY113059A (en) | Controlled-release dosage forms of azithromycin | |
HUP0203523A2 (hu) | Bakteriofágokkal társuló lizáló enzimek használata különböző betegségek megelőzésére és kezelésére | |
DE69322766D1 (de) | Formulierung und verwendung von mikroorganismen zur behandlung von vieh | |
ATE218873T1 (de) | Verwendung von wasser mit verringertem deuterium- gehalt zur herstellung von hygienischen und kosmetischen präparaten | |
ATE496643T1 (de) | Verwendung von antioxidantien zur verhinderung von oxidation und zur reduzierung von wirkstoffzersetzung in wirkstoffhaltigen medizinischen artikeln | |
ATE206051T1 (de) | Verwendung einer zubereitung enthaltend amoxycillin und clavulansäure zur herstellung eines medikaments zur behandlung von bakteriellen infektionen bei pädiatrischen patienten | |
ATE131064T1 (de) | Behandlung zur ermässigung von ödem und muskelschäden. | |
DE59605959D1 (de) | Verwendung von Immunglobulin-Präparationen zur Herstellung eines Medikaments zur oralen Verabreichung zur Behandlung und Prophylaxe chronischer Schmerzzustände | |
ATE190839T1 (de) | Verwendung von prodelphidinen zur behandlung von arthrose | |
ATE106736T1 (de) | Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes. | |
DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
DE59107536D1 (de) | Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose | |
ATE197545T1 (de) | Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus | |
DE69915848D1 (de) | Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte | |
ATE200624T1 (de) | Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis | |
ATE147988T1 (de) | Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände | |
DE3476968D1 (en) | Vaccine and process for its preparation | |
DE3865283D1 (de) | Butylhydroxyanisole zur behandlung von retrovirus-krankheiten. | |
RU4473U1 (ru) | Приспособление для санации женщин с массивной микробной обсемененностью грудного молока | |
Maugh | A New Treatment for Burn Victims: A polymeric synthetic skin has proved useful in limited trials on the severely burned; a newer version looks even better |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: MJÖLKKANNAN FÖRVALTNING AB, TÄBY, SE |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: NESTEC S.A., VEVEY, CH |
|
8339 | Ceased/non-payment of the annual fee |